Clinical Trials Research Reviews

This section of Keeping In Circulation is published periodically to provide information about scientifically useful studies to individuals with PAD and other vascular diseases, as well as to their families, and those at risk. All studies listed will answer an important vascular scientific question and be approved by an Institutional Review Board (IRB). By listing these studies, VDF is not endorsing the studies, the study center, the study sponsor, or the treatments. Information about clinical trials can be found on the VDF Web site at www.vdf.org (click on "Clinical Trials") or in the summer 2004 issue (Volume 4 Number 2) of Keeping in Circulation.

ActivBiotics Study on Leg Pain
Antibiotic Research Study
ActivBiotics is sponsoring a global, multi-center study (PROVIDENCE-1) on the use of an investigational antibiotic in treating intermittent claudication (pain with walking) as the primary symptom of peripheral vascular disease. The PROVIDENCE-1 study is designed with input from world leaders in peripheral arterial disease investigation in order to evaluate the use and benefit of this treatment. For more information and current site locations, please visit www.clinicaltrials.gov/ct/show/NCT00251849?order=18.

Genzyme Corporation Study on Painful Walking
Do you have poor circulation in your legs causing pain when walking?
Novel Gene Transfer Research Study Underway for Leg Pain
If you are 40-80 years old and suffer from blocked leg arteries causing pain brought on by walking (intermittent claudication), you may be eligible to participate in a new research study. The study is underway in the United States and in Europe to assess the safety and effectiveness of an experimental new gene transfer drug being investigated for the potential to treat intermittent claudication. The research study, sponsored by Genzyme Corporation, will determine if the investigational gene transfer drug can increase the growth of new blood vessels and improve blood flow in the legs. Three different doses of the gene transfer drug will be compared to placebo (solution not containing gene transfer substance). For more information and/or to determine your eligibility, visit www.WALKStudy.com

The Vascular Disease Foundation and any sponsors disclaim, either explicitly or implicitly, that the drug, biologic, or device listed here is safe or effective for the purposes under investigation, or that the test article is known to be equivalent or superior to any other drug, biologic, or device. Additionally, no claims are made regarding the scientific utility and conduct of clinical trials or research studies listed.